Immunome director Isaac Barchas sold 100,000 shares for approximately $2.4 million on July 6 and 7, 2026, representing 32% of his total equity holdings. The sale was conducted indirectly through AMBHMC II LLC under a pre-established Rule 10b5-1 trading plan adopted on March 31, 2026. The day after the sale, the FDA accepted the company's lead drug varegacestat for review, with a decision date of April 28, 2027, backed by Phase 3 data showing an 84% lower risk of progression. Following the transaction, Barchas retains 103,259 directly held shares and 108,504 indirectly held shares. Immunome, a clinical-stage oncology company with a market capitalization of $2.3 billion, reported $582.7 million in cash as of March 31, enough to fund operations into 2028, though its net loss widened to $53.8 million last quarter.
Immunome IncDirector sold 32% of holdings day before FDA acceptance; insider sale may signal lack of confidence, but FDA acceptance is positive.